Diagnosis, Etiology, Epidemiology, and Treatment of Head and Neck Tumors in Children and Adolescents

Clascoterone in Winlevi, a topical AR antagonist, is being re-examined due to concerns about HPA axis suppression in adolescents, but it's unlikely to be banned for adult use in androgenetic alopecia (AGA). The European Medicines Agency recommended refusing Winlevi for acne vulgaris, but this may not affect Breezula's approval for AGA.

Stopping dutasteride for a year caused significant hair loss, and resuming it with oral minoxidil led to only partial recovery. Users discuss treatments like finasteride, microneedling, and RU58841, noting mixed results and side effects.

Breezula's phase 3 results are expected soon, with discussions on the effectiveness of androgen receptor antagonists like spironolactone and the potential of GT20029. Users express skepticism about new treatments and discuss the complexities of male pattern baldness, often relying on finasteride despite its side effects.

Gizzela is unsure about the dosage and frequency of copper peptides and asks if they can be used with Stemoxydine. They seek advice on applying these treatments together.

SCUBE3 is available online but poses risks like tumor promotion and high costs. Users advise against using it due to health concerns and inefficacy as a standalone treatment.

Breezula's development has stalled, leaving users disappointed. The conversation includes skepticism about its approval and effectiveness.